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The uremic solutes p-cresol and indoxyl sulfate inhibit endothe-
lial proliferation and wound repair.
Background. Cardiovascular diseases are the major causes
of mortality in uremic patients, and the vascular endothelium
is dysfunctional in uremia. We hypothesized that uremic re-
tention solutes may be among the factors involved in this en-
dothelial dysfunction. We therefore investigated the in vitro
effect of a large panel of uremic retention solutes (guanidino
compounds, polyamines, oxalate, myoinositol, urea, uric acid,
creatinine, indoxyl sulfate, indole-3-acetic acid, p-cresol, hip-
puric acid, and homocysteine) on endothelial proliferation. In
addition, we tested the effect of uremic solutes that altered pro-
liferation on endothelial wound repair.
Methods. Human umbilical vein endothelial cells (HUVEC)
were incubated with uremic retention solutes at concentrations
in the range found in uremic patients. Protein-bound uremic
solutes were also tested in the presence of 4% human albumin.
Then, we determined the effect of each uremic solute on en-
dothelial proliferation by a 5-bromo-2-deoxy-uridine (BrdU)
labeling assay. In addition, confluent endothelial monolayers
were injured, incubated with uremic solutes that altered en-
dothelial proliferation, and the surface of the wound was mea-
sured at different intervals by image analysis.
Results. Endothelial proliferation was inhibited by two
protein-bound uremic retention solutes: p-cresol and indoxyl-
sulfate. Inhibition of endothelial proliferation by p-cresol was
dose-dependent. Moreover, p-cresol and indoxyl sulfate de-
creased endothelial wound repair. The presence of albumin did
not affect the inhibitory effect of these solutes on endothelial
proliferation, but the decrease in endothelial wound repair was
less marked in the presence of albumin.
Conclusion. We demonstrated that both p-cresol and indoxyl
sulfate decrease endothelial proliferation and wound repair.
These solutes could play a role in endothelial dysfunction ob-
served in uremic patients.
Chronic renal failure (CRF) patients display en-
dothelial dysfunction characterized by an impairment
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of endothelium-dependent vasodilatation [1], and an in-
crease in plasma levels of endothelial molecules involved
in vascular tone, hemostasis, or adhesion [2–5]. It has
been suggested that uremic solutes, which accumulate
in CRF patients, are among the factors involved in this
endothelial dysfunction. In vitro, some uremic retention
solutes induce endothelial dysfunction. Homocysteine
up-regulates the gene coding for a stress protein [6],
p-cresol inhibits endothelial cell response to inflamma-
tory cytokines [7], and advanced glycation end products
(AGEs) up-regulate the expression of endothelial adhe-
sion molecules [8], and increase endothelial permeability
[9].
Endothelial dysfunction plays an important role in the
development of cardiovascular diseases [10], which are
the leading cause of mortality in CRF patients [11]. The
physical and metabolic integrity of the endothelium is a
critical element in the prevention or delay of vascular
diseases. In the case of endothelial injury, an active re-
pair process is required. In this view, endothelial ability
to proliferate and migrate plays an important role in the
healing of endothelial injury [12]. It seemed of interest to
analyze the effect of a large panel of uremic solutes on
endothelial cells, and especially on endothelial functions
involved in repair of endothelial injury. We therefore in-
vestigated the in vitro effect of 16 known uremic retention
solutes on endothelial proliferation. These solutes belong
to two groups with different physicochemical characteris-
tics: the free water-soluble compounds (urea, creatinine,
myoinositol, oxalate, uric acid, guanidino compounds,
polyamines), and the protein-bound compounds (indoxyl
sulfate, indole-3-acetic acid, p-cresol, hippuric acid, and
homocysteine). In addition, we studied the effect of ure-
mic solutes that altered proliferation on endothelial re-
pair after wounding in vitro.
METHODS
Reagents
All uremic solutes, listed in Table 1, were obtained
from Sigma (Saint Quentin Fallavier, France), except
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Table 1. Individual solutes under evaluation for screening of
endothelial viability and proliferation
Concentration Molecular
Uremic compound lg/mL weight D References
Free water-soluble
Urea 1200 60.1 14
Creatinine 60 113.1 15
Myoinositol 100 180.2 16
Oxalate 5 90 17
Uric acid 80 168.1 18
Methylguanidine 0.33 73.1 19
c-guanidinobutyric acid 0.02 145.2 14
b-guanidinopropionic acid 0.03 131.1 20
Guanidinosuccinic acid 2.5 175.1 20
Spermine 0.01 202.3 21
Spermidine 0.049 145.2 21
Protein-bound
P-cresol 10 108.1 22
Hippuric acid 50 179.2 18
Indole-3-acetic acid 3.5 175 23
Indoxyl sulfate 25 251.3 24
Homocysteine 2.7 135.2 25
oxalate, which was from Prolabo (Lyon, France).
Methanol was purchased from Carlo Erba (Milano,
Italy), ammonium hydroxide from Sigma, and Tris
from Euromedex (Mundolsheim, France). Endothe-
lial growth medium (EGF)-2 medium was from
Clonetics Biowhittaker (Verviers, Belgium). Trypsin-
ethylenediaminetetraacetic acid (EDTA) solution, Try-
pan Blue, RPMI medium and gelatin were obtained from
Invitrogen (Cergy-Pontoise, France). Fetal bovine serum
(FBS) was from Dominique Dutscher (Brumath, France).
Human serum albumin (HSA) solution 20% was pur-
chased from LFB (Courtaboeuf, France). 5-bromo-2′-
deoxy-uridine (BrdU) Labeling and Detection Kit III was
from Roche (Meylan, France). Annexin V-fluoroscein
isothiocyanate (FITC) Kit was from Immunotech (Mar-
seille, France), tumor necrosis factor (TNF) from Tebu
(Le Perray en Yvelines, France), and cycloheximide from
Sigma.
Endothelial cell culture
Human umbilical vein endothelial cells (HUVEC)
were obtained from umbilical cord vein by collagenase
digestion as previously described [13]. Cells were seeded
on gelatin-coated culture plates and grown in EGM-2
medium under standard cell culture conditions (humid-
ified atmosphere, 5% CO2, 37◦C). Cells were then de-
tached with a 0.05% trypsin-0.02% EDTA solution and
subcultured to the second passage on gelatin-coated cul-
ture plates.
Screening of uremic solutes
The concentrations of the uremic solutes used in this
study (Table 1) are in the range of those reported in
CRF. Protein-bound uremic solutes were analyzed in ab-
sence and in presence of HSA at the concentration found
in human serum (4 g/dL). Each test was performed in
duplicate. P-cresol was diluted from a stock solution pre-
pared in methanol, homocysteine from a stock solution
prepared in Tris buffer 10 mmol/L, and hippuric acid from
a stock solution prepared in ammonium hydroxide. The
other solutes were diluted from stock solutions prepared
in water. Uremic solutes were compared with their re-
spective controls (methanol, Tris, ammonium hydroxide,
or water). Solutes were diluted at least 1/500 in culture
medium to reach mean uremic concentrations. For dose-
response experiments, two solutes, p-cresol and indoxyl
sulfate, were tested at concentrations higher than mean
uremic concentrations. The maximal concentrations of
p-cresol and indoxyl sulfate were obtained by diluting
both stock solutions at 1/200.
The effect of diluents (controls) was also tested. The
dilutions of methanol, Tris buffer, and ammonium hy-
droxide were, respectively, 1/200 (dilution correspond-
ing to the highest dose of p-cresol, 50 lg/mL), 1/250,000
(dilution equivalent to that of homocysteine at uremic
concentration), and 1/2000 (dilution equivalent to that of
hippuric acid at uremic concentration). Since several so-
lutes were diluted in water, the dilution of water tested
was the lowest 1/200 (dilution corresponding to the high-
est dose of indoxyl sulfate, 250 lg/mL).
Endothelial viability assay
The effect of uremic solutes on cell viability was de-
termined by Trypan Blue exclusion. In brief, HUVECs
cultured on 24-well culture plates were incubated during
24 hours with uremic solutes or with their respective con-
trols. After 24 hours, endothelial cells were detached with
trypsin-EDTA solution, Trypan Blue solution was added,
and the percentage of cells excluding Trypan Blue was
determined.
Endothelial cell proliferation assay
The effect of uremic retention solutes or controls
(diluents of solutes) on endothelial cell proliferation
was assessed by BrdU incorporation into cellular DNA.
HUVECs at a concentration of 10,000 cells per well
were seeded on gelatin-coated 96-well culture plates in
EGM-2 medium and cultured during 2 days. Cells were
washed with RPMI, and then uremic solutes at mean
uremic concentration (Table 1) or controls were added
overnight with BrdU. For protein-bound uremic solutes,
experiments were undertaken without and with 4 g/dL
HSA added to the medium. Cell incorporation of BrdU
was measured by enzyme linked immunosorbent assay
(ELISA) with the BrdU Labeling and Detection Kit III,
according to the manufacturer’s instructions. In brief,
cells were fixed, cellular DNA was partially digested by
nuclease treatment, and incorporated BrdU was detected
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with anti-BrdU monoclonal antibodies (mAb) conju-
gated with peroxidase. The absorbance was measured by
a microtiter plate reader (UVmc2) (Safas, Monaco) at
405 nm and was directly correlated to the level of BrdU
incorporation into cellular DNA.
Endothelial apoptosis assay
The effect of p-cresol and indoxyl sulfate on cell apop-
tosis was determined with the annexin V–FITC kit.
HUVECs cultured on 6-well culture plates were incu-
bated with p-cresol at 10 lg/mL, 25 lg/mL, or 50 lg/mL,
or with indoxyl sulfate at 25 lg/mL, 50 lg/mL, 125 lg/mL,
or 250 lg/mL. Nontreated wells received a dilution of
methanol equivalent to p-cresol at the highest concen-
tration or a dilution of water equivalent to indoxyl sul-
fate at the highest concentration. As a positive control
of apoptosis, some cells were incubated with TNF at
25 ng/mL and cycloheximide at 10 lg/mL. After 24 hours,
endothelial cells were detached with trypsin-EDTA solu-
tion, washed in phosphate-buffered saline (PBS) contain-
ing 20% FBS, centrifuged, and washed with ice-cold PBS.
After centrifugation, the pellet was resuspended in bind-
ing buffer containing annexin V–FITC and propidium
iodide, mixed gently, and incubated on ice for 10 minutes
in the dark. The samples were then read in an Epics
XL flow cytometer (Beckman-Coulter, Roissy, France)
at 488 nm excitation. A 515 nm bandpass filter for FITC
detection, and a >600 nm filter for propidium iodide de-
tection were used. The percentage of annexin V–positive
cells in the endothelial cell population was determined
by the System IITM software (Beckman-Coulter, Roissy,
France).
Endothelial wound repair
Confluent endothelial monolayers cultured on gelatin-
coated 24-well culture plates were wounded with a yellow
tip, washed with RPMI, and p-cresol or indoxyl sulfate
at different concentrations was added. To avoid differ-
ences due to wound size, experiments were performed
on wounds of equivalent sizes. Experiments were under-
taken without and with 4 g/dL HSA added to the medium.
Cell wound repair was analyzed under videomicroscopy
coupled with a software system allowing image analysis
(Biocom, Les Ulis, France). The surface of the wound
was measured at time 0, and after 5 and 24 hours. Cell
wound repair was calculated by subtracting the area ob-
tained in the presence of uremic solutes or controls at
5 and 24 hours of incubation from the area of the orig-
inal wound (measured at time 0 before the addition of
uremic solutes or controls). The area obtained after cell
migration was expressed as a percentage of the area of
the original wound, considered as 100%. A linear regres-
sion curve was obtained by plotting the values of areas
Fig. 1. Effect of free water-soluble uremic solutes on endothelial cell
proliferation. Endothelial cells were incubated in medium without and
with free water-soluble solutes at mean uremic concentrations. After
incubation, endothelial cell proliferation was measured by enzyme-
linked immunosorbent assay (ELISA) analyzing 5-bromo-2-deoxy-
uridine (BrdU) incorporation. Data are expressed as mean ± SEM.
The number of experiments is between brackets.
obtained after cell migration versus time. The slope of the
curve reflects the speed of cell wound repair.
Statistical analysis
Data are expressed as mean ± standard error of the
mean (SEM). Statistical analysis was performed with the
Prism software (GraphPad Software, Inc., San Diego,
CA, USA). Determination of significant differences was
performed by the Student paired t test or by analysis
of variance (ANOVA) followed by a Bonferroni test. A
P value lower than 0.05 was considered significant.
RESULTS
Effect of uremic retention solutes on endothelial
cell proliferation
We measured endothelial cell proliferation by ELISA
analyzing BrdU incorporation into cellular DNA, after
incubation with uremic solutes at mean uremic concen-
tration (Table 1). Among the different free water-soluble
solutes tested, none impaired endothelial proliferation
(Fig. 1).
The effect of protein-bound uremic solutes was ana-
lyzed without and with HSA at concentrations found in
human serum (4 g/dL). The results obtained for protein-
bound uremic solutes are shown in Figure 2. Among
the different protein-bound solutes tested, p-cresol and
indoxyl sulfate inhibited endothelial proliferation. With-
out HSA (Fig. 2A), p-cresol and indoxyl sulfate inhibited
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Fig. 2. Effect of protein-bound uremic so-
lutes on endothelial cell proliferation. En-
dothelial cells were incubated with protein-
bound solutes at mean uremic concentrations
or with control medium, without (A) or with
(B) of 4% human serum albumin (HSA). Af-
ter incubation, endothelial cell proliferation
was measured by enzyme-linked immunosor-
bent assay (ELISA) analyzing 5-bromo-2-
deoxy-uridine (BrdU) incorporation. Data
are expressed as mean ± SEM of change in
proliferation versus control. The number of
experiments is between brackets. Determina-
tion of significant differences versus control
was performed by the Student paired t test.
∗P < 0.05 vs. control; ∗∗∗P < 0.001 vs. control.
endothelial proliferation by 26% (P < 0.001 vs. control)
and 21% (P < 0.001 vs. control), respectively. With HSA
(Fig. 2B), the inhibition of endothelial proliferation in-
duced by p-cresol and indoxyl sulfate was 26% (P < 0.001
vs. control) and 15% (P < 0.05 vs. control), respectively
(Fig. 2B).
To investigate whether their diluents would mask a pos-
sible effect of the solutes tested, we analyzed the effect
of the different diluents (methanol, Tris, ammonium hy-
droxide, and water) on endothelial proliferation. No dif-
ference in endothelial proliferation was noted between
cells incubated with diluents and cells incubated with cul-
ture medium alone (Fig. 3).
We performed dose-response experiments analyzing
the effect of p-cresol (Fig. 4) and indoxyl sulfate (Fig. 5)
on endothelial proliferation, without and with HSA.
Without HSA, p-cresol at 10 lg/mL, 25 lg/mL, and
50 lg/mL induced a decrease in endothelial cell prolif-
eration of 21% (P < 0.001 vs. control), 38% (P < 0.001
vs. control), and 54% (P < 0.001 vs. control), respectively
(Fig. 4A), compared to cells exposed to control medium.
The decrease in endothelial proliferation induced by
p-cresol was dose-dependent (Fig. 4). With HSA, p-cresol
inhibited endothelial cell proliferation, in the same way
as without HSA (Fig. 4B).
Without HSA, all concentrations of indoxyl sulfate
(25 lg/mL, 50 lg/mL, 125 lg/mL, and 250 lg/mL) inhib-
ited endothelial proliferation relative to control medium,
but the inhibition was not dose-dependent (Fig. 5A). With




















Fig. 3. Effect of diluents of uremic solutes on endothelial cell prolif-
eration. Endothelial cells were incubated with culture medium sup-
plemented or not with diluents of uremic solutes. After incubation,
endothelial cell proliferation was measured by enzyme-linked im-
munosorbent assay (ELISA) analyzing 5-bromo-2-deoxy-uridine
(BrdU) incorporation. Data are expressed as mean ± SEM of six inde-
pendent experiments.
dothelial proliferation, but this inhibition was less pro-
nounced than without HSA (Fig. 5B).
Effect of uremic retention solutes on endothelial
cell viability
To investigate whether uremic retention solutes would
affect endothelial viability, endothelial cells were incu-
bated during 24 hours with uremic solutes at mean ure-
mic concentration or with control mediums. In addition,
for p-cresol and indoxyl sulfate, a dose-response curve
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Fig. 4. Effect of p-cresol (pc) on endothelial cell proliferation.
Endothelial cells were incubated in medium without and with differ-
ent concentrations of p-cresol. Experiments were undertaken with-
out (A) and with (B) 4% human serum albumin (HSA) added to the
medium. After incubation, endothelial cell proliferation was measured
by enzyme-linked immunosorbent assay (ELISA) analyzing 5-bromo-
2-deoxy-uridine (BrdU) incorporation. Data are expressed as mean
± SEM of seven (A) or ten (B) independent experiments. Determi-
nation of significant differences was performed by analyis of variance
(ANOVA) followed by a Bonferroni’s multiple comparison test. ∗∗P <
0.01 vs. control; ∗∗∗P < 0.001 vs control.
was obtained: HUVEC were incubated with p-cresol at
10 lg/mL, 25 lg/mL, and 50 lg/mL and with indoxyl sul-
fate at 25 lg/mL, 50 lg/mL, 125 lg/mL, and 250 lg/mL.
After 24 hours, endothelial cell viability was not impaired
by the different uremic solutes tested, whatever the dose
used (data not shown).
Effect of p-cresol and indoxyl sulfate on endothelial
cell apoptosis
To investigate whether p-cresol and indoxyl sulfate
would induce endothelial cell apoptosis, we measured
their effect on the percentage of annexin V–positive cells.
This percentage was not increased after incubation with
p-cresol and indoxyl sulfate (Table 2), showing that these
two solutes did not induce endothelial apoptosis. As ex-
pected, cells treated with TNF and cycloheximide, used
as a positive control of endothelial apoptosis, displayed a
strong increase in annexin V staining (Table 2).
Effect of p-cresol and indoxyl sulfate on endothelial
wound repair
Since p-cresol and indoxyl sulfate inhibited endothe-
lial proliferation, we evaluated whether these two
compounds would affect endothelial wound repair.
Endothelial monolayers were wounded, and wound
repair was analyzed after incubation with p-cresol and
indoxyl sulfate at different concentrations, without and
with HSA. Without HSA, endothelial wound repair in
monolayers exposed to p-cresol was significantly lower
than in cells exposed to control medium (Figs. 6 and 7A).
P-cresol at 10 lg/mL, 25 lg/mL, and 50 lg/mL reduced en-
dothelial wound repair by 19% (P <0.01 vs. control), 28%
(P < 0.001 vs. control), and 40% (P < 0.001 vs. control),
respectively (Fig. 7A). With HSA, only p-cresol at 50 lg/
mL significantly inhibited endothelial wound repair (Fig.
7B). Without HSA, indoxyl sulfate at concentrations of
125 lg/mL and 250 lg/mL reduced endothelial wound
repair (Fig. 8A). Endothelial wound repair was inhibited
by 22% (P < 0.01 vs. control) and by 33% (P < 0.001
vs. control) by indoxyl sulfate, respectively, at 125 lg/
mL and 250 lg/mL. With HSA, indoxyl sulfate decreased
endothelial wound repair, but to a lesser extent than with-
out HSA (Fig. 8B).
DISCUSSION
The dysfunction of the endothelium plays a key role in
the development of cardiovascular diseases [10], which
account for about 50% of mortality in CRF patients [11].
Endothelium dysfunction has been clearly demonstrated
in CRF patients [1, 4, 5, 26]; however, the mechanisms
involved are still obscure. In CRF patients, endothelial
cells are in permanent contact with uremic retention so-
lutes and could be a privileged target of these solutes.
Endothelial cell dysfunction therefore seems to be an
adequate gauge for selecting potentially harmful uremic
solutes. In this way, the present study was designed to
investigate the short-term effect of uremic solutes on en-
dothelial proliferation in vitro in order to determine the
solutes with the most harmful effect. The solutes were
tested at uremic concentrations and under identical con-
ditions. We showed that two solutes, p-cresol and indoxyl
sulfate, at concentrations commonly found in uremia, in-
duced an inhibition of endothelial proliferation. The in-
hibition of endothelial proliferation induced by p-cresol
was dose-dependent. On the contrary, the inhibition of
endothelial proliferation induced by indoxyl sulfate was
not dose-dependent. This result suggests indoxyl sulfate
has plateau effect at the concentration range used in this
study. It does not exclude that higher concentrations of
indoxyl sulfate might have a dose-dependent effect. How-
ever, concentrations higher than those tested in this study
(i.e., much higher than those in uremic patients) should
be considered nonrelevant to the in vivo situation.
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Fig. 5. Effect of indoxyl sulfate (IS) on en-
dothelial cell proliferation. Endothelial cells
were incubated in medium without and with
increasing concentration of indoxyl sulfate.
Experiments were undertaken without (A)
and with (B) 4% human serum albumin
(HSA) added to the medium. After in-
cubation, endothelial cell proliferation was
measured by enzyme-linked immunosorbent
assay (ELISA) analyzing 5-bromo-2-deoxy-
uridine (BrdU) incorporation. Data are ex-
pressed as mean ± SEM of five (A) or seven
(B) independent experiments. Determina-
tion of significant differences was performed
by analysis of variance (ANOVA) followed
by a Bonferroni’s multiple comparison test.
∗P < 0.05 vs. control; ∗∗P < 0.01 vs. control;
∗∗∗P < 0.001 vs. control.




Control (methanol) 3.6 ± 0.6
p-cresol 10 lg/mL 3.4 ± 0.4
p-cresol 25 lg/mL 4.3 ± 1.0
p-cresol 50 lg/mL 4.5 ± 0.5
Control (water) 3.8 ± 0.8
Indoxyl sulfate 25 lg/mL 4.2 ± 1.6
Indoxyl sulfate 50 lg/mL 4.3 ± 0.8
Indoxyl sulfate 125 lg/mL 3.7 ± 0.5
Indoxyl sulfate 250 lg/mL 4.4 ± 1.2
Tumor necrois factor/cycloheximide 33.2 ± 2.9
Endothelial cells were incubated during 24 hours in medium without and with
different concentrations of p-cresol, or in medium without and with different con-
centrations of indoxyl sulfate. Cells incubated with tumor necrosis factor (TNF)
and cycloheximide during 24 hours were used as a positive control of apopto-
sis. After incubation, the percentage of annexin V–positive endothelial cells was
determined by flow cytometry. Data are expressed as mean ± SEM of five inde-
pendent experiments.
The other uremic solutes tested (urea, creatinine,
myoinositol, oxalate, uric acid, c-guanidinobutyric acid,
b-guanidinopropionic acid, guanidinosuccinic acid,
methylguanidine, spermine, spermidine, hippuric acid,
indole-3-acetic acid, and homocysteine) had no signif-
icant effect on endothelial proliferation. We cannot
exclude the possibility that solutes having no effect in the
present study may have an effect in studies performed
with longer times of incubation or higher solute concen-
trations. Indeed, oxalate at uremic concentration inhibits
endothelial cell replication, but this was observed after
more than 10 days of incubation [27]. In addition,
homocysteine inhibits endothelial cell proliferation but
at higher concentrations than those encountered in
uremia [28, 29].
P-cresol (4-methylphenol) and indoxyl sulfate are
protein-bound uremic solutes. P-cresol is an end product
of protein catabolism produced by intestinal bacteria as
a metabolite of tyrosine and phenylalanine [30]. Indoxyl
sulfate is metabolized by the liver from indole produced
by the intestinal flora as a metabolite of tryptophan [31].
In the uremic rat, indoxyl sulfate accelerates glomerular
sclerosis [32] and its accumulation promotes the progres-
sion of CRF [33]. In CRF patients, serum levels of p-cresol
and indoxyl sulfate are increased about 10-fold [34] and
50-fold [24], respectively. In healthy subjects, the protein
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Fig. 6. Pictures of endothelial wound repair in presence of p-cresol. En-
dothelial monolayers were wounded, incubated with control medium
or with p-cresol, and endothelial wound repair was analyzed under
videomicroscopy. Pictures of wounds before addition of control medium
(A) or p-cresol (C). Pictures of wounds after a 24-hour incubation with
control medium (B) or with p-cresol at 50 lg/mL (D). In presence of
control medium, the original wound was almost completely repaired
after 24 hours of incubation (A and B). In presence of p-cresol, wound
repair was inhibited (C and D).
binding of these solutes is close to 100% [24, 34]. In CRF
patients, approximately 90% of p-cresol [34] and 85% of
indoxyl sulfate [24] are protein-bound.
In the present study, p-cresol and indoxyl sulfate de-
creased endothelial repair after wounding in vitro. The
healing of endothelial injury requires an active repair
process, closely related to the endothelial capacity to pro-
liferate and to migrate. When endothelial integrity is dis-
rupted, the cytoskeletal systems are activated to regulate
cell migration and proliferation, in order to reestablish
endothelial integrity [12]. In resting confluent endothe-
lial cells, the actin cytoskeleton is organized as a dense
peripheral band of actin microfilaments and as central mi-
crofilaments [35]. After injury, the dense peripheral band
of actin microfilaments is reduced, forward actin-based
lamellipodia extrusions are formed, and cells are elon-
gated [36]. The presence and the reorganization of cen-
tral microfilaments, associated with lateral cell spreading,
lead to cell migration and proliferation [36].
The mechanisms by which p-cresol and indoxyl sulfate
inhibit endothelial proliferation and wound repair are un-
known. The inhibition observed in the present study was
not attributable to cellular death because p-cresol and
Fig. 7. Effect of p-cresol (pc) on repair of wounded endothelial mono-
layers. Endothelial monolayers were wounded and incubated with
increasing concentrations of p-cresol. Experiments were undertaken
without (A) and with (B) 4% human serum albumin (HSA) added to
the medium. Endothelial wound repair was analyzed under videomi-
croscopy. Data are expressed as mean ± SEM of six independent ex-
periments. Determination of significant differences was performed by
analysis of variance (ANOVA) followed by a Bonferroni’s multiple
comparison test. ∗∗P < 0.01 vs. control; ∗∗∗P < 0.001 vs. control.
indoxyl sulfate did not affect endothelial viability and
did not induce endothelial apoptosis. We have previously
shown that p-cresol modifies the actin cytoskeleton or-
ganization in endothelial cells [abstract; Cerini C et al,
J Am Soc Nephrol 12: 810, 2001]. We can therefore sup-
pose that its inhibitory effect on endothelial proliferation
and wound repair could be partly related to its effects
on the endothelial actin cytoskeleton. To our knowledge,
there is no information on the effect of indoxyl sulfate
on endothelial cells. This study is the first to demonstrate
such an effect, and further studies are necessary to under-
stand the molecular mechanism of indoxyl sulfate action
on endothelial cells.
Since p-cresol and indoxyl sulfate are protein-bound in
plasma, we supplemented the culture medium with hu-
man albumin at concentrations found in human plasma.
Without albumin, indoxyl sulfate inhibited endothelial
proliferation and wound repair. A similar result was
observed with albumin, but at a lower level of significance.
The presence of albumin did not affect the inhibitory
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Fig. 8. Effect of indoxyl sulfate (IS) on re-
pair of wounded endothelial monolayers. En-
dothelial monolayers were wounded and in-
cubated with increasing concentrations of in-
doxyl sulfate. Experiments were undertaken
without (A) and with (B) 4% human serum
albumin (HSA) added to the medium. En-
dothelial wound repair was analyzed un-
der videomicroscopy. Data are expressed as
mean ± SEM of six independent experiments.
Determination of significant differences was
performed by analysis of variance (ANOVA)
followed by a Bonferroni’s multiple compar-
ison test. ∗∗P < 0.01 vs. control; ∗∗∗P < 0.001
vs. control.
effect of p-cresol on endothelial proliferation, but it
decreased its inhibitory effect on wound repair. These dif-
ferences could be explained by the decrease in the free
nonprotein-bound fraction of these solutes in medium
supplemented with albumin. The results obtained with
p-cresol suggest the free fraction of p-cresol has different
impacts on endothelial wound repair and on endothelial
proliferation.
That two protein-bound uremic solutes induced en-
dothelial dysfunction in vitro is of importance because
the removal of protein-bound uremic solutes by dialysis
therapy is unsatisfactory. Only 30% of p-cresol and in-
doxyl sulfate is removed by hemodialysis therapies, which
eliminate over 70% of urea and creatinine [15]. Other
solutions should be developed to remove protein-bound
uremic solutes like p-cresol and indoxyl sulfate. An al-
ternative solution is to reduce the intestinal load of these
solutes. A low-protein diet decreases serum levels and
daily urinary excretion of p-cresol [37] and indoxyl sul-
fate [38]. In addition, the oral sorbent AST-120 decreases
p-cresol and indoxyl sulfate levels in the uremic rat and
in uremic patients [39–42], and delays the deterioration
of renal function in patients [41, 42].
An increasing pathophysiologic role has been at-
tributed recently to the protein-bound uremic solutes
[43], of which at least 20 different moieties are known
at present [44]. Among those, the most important bio-
chemical/biological effects can be summarized as follows:
p-cresol, inhibition of leukocyte function [45, 7], neu-
ronal cell dysfunction [46]; indoxyl sulfate, decline in
residual renal function [47], neuronal dysfunction [46];
homocysteine, vascular disease [48]. A more extended
summary of the pathophysiologic role of the protein-
bound uremic solutes can be found in review publications
[30, 31, 43]. Until recently, there was no evidence that the
protein-bound uremic solutes had a clinical impact. De
Smet et al [49], however, demonstrated a link between
hospitalization rate and hospitalization because of infec-
tion in one hand, and free plasma p-cresol levels on the
other.
450 Dou et al: Uremic solutes and endothelial dysfunction
CONCLUSION
We showed that two protein-bound uremic solutes,
p-cresol and indoxyl sulfate, inhibit endothelial cell pro-
liferation and wound repair in vitro. These protein-bound
solutes are poorly removed by hemodialysis therapies. In
addition, endothelial cells from patients are chronically
exposed to these solutes, so one can suppose that the in
vivo effects of p-cresol and indoxyl sulfate may be even
more prominent in patients. This study suggests that these
solutes may participate in endothelial dysfunction in CRF
patients.
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